We finally showed that non-responders to anti-PD-1 and/or anti-CTLA-4 ICI therapies have lower IFNG, Merck18, CD274 and CD8 scores, and lower dysfunction of the tumor. This evidence concerns the gene CTLA4 and neoplasm.